# US 2023/0265097 A1 · Salts and forms of a wee1 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265097 A1
- Document ID: US20230265097A1
- Status: Published application
- Kind: A1
- Application number: 18/004,628
- Filed: 2021-07-08
- Published: 2023-08-24
- Earliest claimed: 2020-07-09
- Assignees: Recurium IP Holdings, LLC
- Applicants: Recurium IP Holdings, LLC
- Inventors: Chad Daniel Hopkins; Peter Qinhua Huang; Kevin Duane Bunker
- Web page: https://patentgrep.com/patent/US20230265097A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The salt, such as adipate salt Form A, and freebase forms of Compound A are WEE inhibitors. Such salts and/or forms and freebase forms, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

## Claims

### Claim 1

(R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (Compound A):
wherein Compound A is a crystalline freebase form or a pharmaceutically acceptable salt form.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a crystalline freebase form of Compound A.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the crystalline freebase form is selected from the group consisting of freebase Form A of Compound A, freebase Form B of Compound A, freebase Form C of Compound A, freebase Form D of Compound A, freebase Form E of Compound A, freebase Form F of Compound A, freebase Form G of Compound A, freebase Form H of Compound A, freebase Form I of Compound A and freebase Form J of Compound A.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt form of Compound A.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the pharmaceutically acceptable salt form of Compound A is selected from the group consisting of adipate salt Form A, HCl salt Form A, HCl salt Form B, sulfate salt Form A, sulfate salt Form B, mesylate salt Form A, maleate salt Form A, phosphate salt Form A, tartrate salt Form A, tosylate salt Form A, mucate salt Form A and hippurate salt Form A.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the pharmaceutically acceptable salt form of Compound A is adipate salt Form A.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from 15.40 degrees 2θ±0.2 degrees 2θ, 16.58 degrees 2θ±0.2 degrees 2θ, 22.12 degrees 2θ±0.2 degrees 2θ or 22.88 degrees 2θ±0.2 degrees 2θ.

### Claim 8 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A has an X-ray powder diffraction pattern spectrum corresponding to the representative X-ray powder diffraction pattern depicted in FIG. 1B.

### Claim 9 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A is characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm in the range of about 75° C. to about 183° C.

### Claim 10 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A is characterized by a DSC thermogram comprising an endotherm at approximately 179° C.

### Claim 11 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A is characterized by a weight loss of about 2.3% when heated from about 29° C. to about 150° C.

### Claim 12 (depends on 6)

The compound of claim 6, wherein the adipate salt Form A has a DSC and/or thermogravimetric analysis (TGA) thermogram corresponding to the representative DSC and/or TGA thermogram depicted in FIG. 2.

### Claim 13 (depends on 3)

The compound of claim 3, wherein the crystalline freebase form is crystalline freebase Form E of Compound A.

### Claim 14 (depends on 13)

The compound of claim 13, wherein the freebase Form E is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from 6.20 degrees 2θ±0.2 degrees 2θ, 12.40 degrees 2θ±0.2 degrees 2θ, 18.96 degrees 2θ±0.2 degrees 2θ or 22.62 degrees 2θ±0.2 degrees 2θ.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the freebase Form E has an X-ray powder diffraction pattern spectrum corresponding to the representative X-ray powder diffraction pattern depicted in FIG. 31.

### Claim 16 (depends on 13)

The compound of claim 13, wherein the freebase Form E is characterized by a DSC thermogram comprising an endotherm in the range of about 105° C. to about 125° C.

### Claim 17 (depends on 13)

The compound of claim 13, wherein the freebase Form E is characterized by a DSC thermogram comprising an endotherm at approximately 115° C.

### Claim 18 (depends on 13)

The compound of claim 13, wherein the freebase Form E is characterized by a weight loss of about 3.8% when heated from about 28 to ° C. about 150° C.

### Claim 19 (depends on 13)

The compound of claim 13, wherein the freebase Form E has a DSC and/or TGA thermogram corresponding to the representative DSC and/or TGA thermogram depicted in FIG. 32.

### Claim 20 (depends on 13)

The compound of claim 13, wherein the freebase Form E is a hydrate.

### Claim 21 (depends on 3)

The compound of claim 3, wherein the crystalline freebase form is crystalline freebase Form F of Compound A.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the freebase Form F is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from 5.14 degrees 2θ±0.2 degrees 2θ, 6.24 degrees 2θ±0.2 degrees 2θ, 10.19 degrees 2θ±0.2 degrees 2θ or 12.40 degrees 2θ±0.2 degrees 2θ.

### Claim 23 (depends on 21)

The compound of claim 21, wherein the freebase Form F has an X-ray powder diffraction pattern spectrum corresponding to the representative X-ray powder diffraction pattern depicted in FIG. 33.

### Claim 24 (depends on 21)

The compound of claim 21, wherein the freebase Form F is characterized by a DSC thermogram comprising an endotherm in the range of about 163° C. to about 171° C.

### Claim 25 (depends on 21)

The compound of claim 21, wherein the freebase Form F is characterized by a DSC thermogram comprising an endotherm at approximately 167° C.

### Claim 26 (depends on 21)

The compound of claim 21, wherein the freebase Form F is characterized by a weight loss of about 0.9% when heated from about 22° C. to about 150° C.

### Claim 27 (depends on 21)

The compound of claim 21, wherein the freebase Form F has a DSC and/or TGA thermogram corresponding to the representative DSC and/or TGA thermogram depicted in FIG. 34.

### Claim 28 (depends on 21)

The compound of claim 21, wherein the freebase Form F is an anhydrate.

### Claim 29 (depends on 3)

The compound of claim 3, wherein the crystalline freebase form is crystalline freebase Form J of Compound A.

### Claim 30 (depends on 29)

The compound of claim 29, wherein the freebase Form J is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from 6.08 degrees 2θ±0.2 degrees 2θ, 10.58 degrees 2θ±0.2 degrees 2θ, 19.42 degrees 2θ±0.2 degrees 2θ, 21.93 degrees 2θ±0.2 degrees 2θ or 23.23 degrees 2θ±0.2 degrees 2θ.

### Claim 31 (depends on 29)

The compound of claim 29, wherein the freebase Form J has an X-ray powder diffraction pattern spectrum corresponding to the representative X-ray powder diffraction pattern depicted in FIG. 40.

### Claim 32 (depends on 29)

The compound of claim 29, wherein the freebase Form J is an anhydrate.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A pharmaceutical composition comprising an effective amount of the crystalline form of any one of claims 1-32, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

Use of an effective amount of a compound of any one of claims 1-32 in the manufacture of a medicament for ameliorating or treating a malignant growth or tumor, wherein the malignant growth or tumor is due to a cancer selected from a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma and a non-Hodgkin's lymphoma.

### Claim 35 (depends on 34)

The use of claim 34, wherein the cancer is a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer or a vulvar cancer.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A compound of any one of claims 1-32 for use in ameliorating or treating a malignant growth or tumor, wherein the malignant growth or tumor is due to a cancer selected from a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma and a non-Hodgkin's lymphoma.

### Claim 37 (depends on 36)

The compound of claim 36, wherein the cancer is a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer or a vulvar cancer.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for ameliorating or treating a malignant growth or tumor comprising administering an effective amount of a compound of any one of claims 1-32 to a subject in need thereof, wherein the malignant growth or tumor is due to a cancer selected from a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma and a non-Hodgkin's lymphoma.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for ameliorating or treating a malignant growth or tumor comprising contacting the malignant grown or tumor with an effective amount of a compound of any one of claims 1-32 to a subject in need thereof, wherein the malignant growth or tumor is due to a cancer selected from a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma and a non-Hodgkin's lymphoma.

### Claim 40 (depends on 38, 39)

The method of claim 38 or 39, wherein the cancer is a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer or a vulvar cancer.
